Novanta Inc. (NOVT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive aspects such as strong bookings growth, advanced surgery business growth, and promising new product launches, there are concerns with the decline in precision medicine sales and uncertain life sciences outlook. The Q&A reveals cautious guidance and unresolved tariff issues. The positive impact of the Kion acquisition and potential growth in warehouse robotics is offset by uncertainties in organic growth and market recovery, leading to a neutral stock price prediction.
Key Financial Performance
Revenue $241 million, representing reported revenue growth of 2% and organic revenue declines of 2%. The growth was driven by new product revenue growing over 50% year-over-year and customer orders increasing 10% year-over-year.
Adjusted Gross Margins 46%, down slightly from 46.6% in Q2 2024. The decline was attributed to increased tariff costs.
Adjusted EBITDA Margin 22%, showing growth of 2% year-over-year. This reflects operational efficiency and cost management.
R&D Expenses $25 million, approximately 10% of sales, reflecting continued investment in innovation.
SG&A Expenses $45 million, approximately 19% of sales, excluding ERP design costs.
Operating Cash Flow $15 million, down from $41 million in Q2 2024. The decrease was due to timing of tax payments, increased inventory purchases, and the Kion acquisition.
Net Debt $355 million, with a net leverage ratio of approximately 1.7x. This reflects the acquisition of Kion Technologies and increased borrowing capacity.
Bookings 10% growth year-over-year and 20% sequentially, with a book-to-bill ratio of 1.02, indicating strengthening backlog and demand.
Medical Market Sales 54% of total sales, with Advanced Surgery business experiencing 17% growth year-over-year due to strong patient procedural growth and new product launches.
Precision Medicine Business 13% decline in sales year-over-year but grew 10% sequentially, driven by a shift to advanced technologies like RFID and machine vision.
Automation Enabling Technologies Segment Revenue 4% growth year-over-year, driven by a 16% increase in the Robotics and Automation business unit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New product revenue: Grew by over 50% year-over-year, with a goal of $50 million incremental new product sales in 2025.
Advanced Surgery business: New product launches in surgical robotics and minimally invasive surgery applications are ramping successfully, expected to nearly double revenue by 2030.
Design wins: Two major design wins in minimally invasive surgery market, including a third-generation insufflator device and a next-generation pump for endoscopy towers.
Robotics and automation: Strong demand with double-digit revenue growth in Q2 2025. Sales expected to double in 2026 and again in 2027.
Medical device markets: Sustained double-digit growth driven by patient procedure growth rates and hospital spending.
Warehouse automation: Signed a $50 million contract with a leading e-commerce and warehouse robotics company, representing a $1 billion addressable market by 2030.
India expansion: Expanding commercial presence in India with recent success in winning new customers.
Tariff response strategy: Strong execution of tariff mitigation strategies, including regional manufacturing shifts.
Cost reduction plans: Launched plans to simplify operating model and improve gross margins, with $20-$25 million restructuring charges expected.
Kion acquisition: Integration on track, exceeding expectations, and contributing to sales growth.
Portfolio evolution: Focus on high-growth medical markets, recurring consumables, and intelligent subsystems with embedded software.
Acquisition strategy: Large pipeline of targets with plans to pursue additional transactions in H2 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Costs and Trade Disruptions: The company faces increased costs due to tariffs, with a $4 million net impact year-to-date. Trade disruptions, particularly between the U.S. and China, have led to muted customer orders from Chinese customers and necessitated a shift in production to non-tariff regions. This has also resulted in temporary redundancy costs from the regional manufacturing strategy.
Precision Medicine Business Challenges: The Precision Medicine business experienced a 13% year-over-year decline in sales due to weak end-market dynamics, including disruptions at the U.S. NIH and FDA, weak biotech funding, and cutbacks in pharma CapEx. These factors have caused revenue instability, although sequential growth was observed.
Industrial Capital Equipment Market Decline: Sales to industrial capital equipment markets declined year-over-year, particularly in China, due to trade disruptions and customer demand impacts. Although revenue has stabilized, it remains at a lower level.
Life Science Equipment Market Weakness: The life science equipment market saw a decline due to weak biotech funding, disruptions at the U.S. NIH and FDA, and trade disruptions. Customers are accelerating the replacement cycle away from older technologies, but the transition to advanced technologies is still in progress.
Global Trade and Economic Uncertainty: The fluid and ever-changing nature of global trade agreements and tariffs poses risks to the company's operations and financial performance. This includes potential further disruptions in end-market demand and increased costs.
Cash Flow and Inventory Management: Operating cash flow decreased year-over-year, primarily due to the timing of tax payments, increased inventory purchases to mitigate global trade dynamics, and the acquisition of Kion. This has impacted cash flow conversion rates, although improvements are expected in the third quarter.
Regulatory and Funding Disruptions: Disruptions at the U.S. NIH and FDA, along with weak biotech funding, have negatively impacted the Precision Medicine and life science equipment markets, causing revenue declines and market instability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Novanta expects full year 2025 GAAP revenue to be approximately $970 million to $985 million, representing overall revenue growth of 2% to 4%. For the third quarter of 2025, GAAP revenue is expected to range from $244 million to $247 million, reflecting flat to 1% year-over-year growth and sequential growth of 1% to 2%.
Margin Projections: Adjusted gross margins for the full year 2025 are expected to be approximately 46%, including the impact of tariffs and regional manufacturing strategy costs. Excluding these costs, the company would achieve 100 basis points of gross margin expansion. Adjusted EBITDA for 2025 is projected to be $225 million to $230 million, representing a 23% EBITDA margin and year-over-year growth of 7% to 10%.
Capital Expenditures and Cost Management: Novanta is implementing a regional manufacturing strategy and cost reduction plans, expected to result in $20 million to $25 million in restructuring charges, with savings materializing in Q4 2025 and into 2026. The company is also focusing on inventory management and lower cash taxes to improve cash flow in the second half of 2025.
Advanced Surgery Business Growth: The Advanced Surgery business is expected to nearly double its revenue by 2030, growing from $200 million in 2024. New product launches in surgical robotics and minimally invasive surgery applications are ramping successfully, with $50 million in incremental new product revenue anticipated for 2025.
Robotics and Automation Growth: Sales in robotics and automation applications are expected to double in 2026 compared to 2025 and double again in 2027. This growth is driven by demand for physical AI applications such as warehouse automation and humanoid robotics, representing a $1 billion addressable market by 2030.
Precision Medicine Business Outlook: The Precision Medicine business is expected to stabilize over the next several quarters and grow sequentially for the remainder of 2025, driven by a shift to advanced technologies like RFID and machine vision.
Acquisition Strategy: Novanta plans to pursue additional acquisitions in the second half of 2025, focusing on high-growth medical markets, recurring consumable-based revenue, and embedded software and intelligent subsystems. The company has a large pipeline of targets and is well-positioned financially to execute transactions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you break down your revenue guidance in terms of growth from Kion, the impact of FX, and the true organic growth?
A:For the full year, the organic growth is expected to be in the range of -1% to +1%. The FX impact is consistent with the second quarter and carried forward for the full year. The delta is primarily due to the Kion acquisition, which has performed significantly better than expected.
Q:What are the biggest drivers of organic growth in 2026 in terms of new products?
A:The drivers include advanced surgery product ramps, physical AI-enabled robotics for warehouse automation, industrial physical AI applications expected to double in 2026 versus 2025, and strong design wins in areas like additive manufacturing driven by aerospace and medical sectors. Additionally, advanced material processing applications supporting on-device AI investments are also key growth areas.
Q:Have we seen the low point for the year in Industrial and Precision Medicine, and what is the outlook for 2026?
A:Based on current bookings and customer outlook, the Industrial business has likely reached its low point and is expected to improve sequentially. Precision Medicine is also expected to improve sequentially due to technology shifts like machine vision and RFID transitions, despite market dynamics not improving in the near term. The outlook for life sciences remains unclear.
Q:What is the status of the $35 million held up due to China tariffs?
A:The $35 million is factored into the guidance with caution, assuming it will not be recovered yet. The uncertainty around tariffs has impacted order behavior. However, local sales in China are growing, with total China sales up 15% year-over-year. Design win activities with Chinese customers have also accelerated, indicating potential recovery by Q4, though it is not yet factored into the guidance.
Q:Are the design wins in China mostly industrial, medical, or robotic surgery?
A:The design wins in China are mostly industrial and robotics, with limited exposure to humanoids. The bulk of humanoid exposure is in U.S. and European markets.
Q:Can you provide more details about the warehouse robotics win and its potential future growth?
A:The warehouse robotics win involves advanced sensing and motion technologies, enabling robots to mimic human touch and movement with extreme accuracy. The $50 million contract is part of a multiyear deployment cycle, and the served available market for physical AI applications is estimated to be $1 billion by 2030. Novanta aims to capture a significant share of this market.
Q:Does the warehouse automation contract include the entire package of offerings like force torque, servo drives, and encoders?
A:Yes, the contract includes both sensing capabilities and servo drives. Novanta's unique capabilities in small form factor, precision, and reliability make it well-suited for these applications.
Q:Do you need to add additional capacity for the ramp in new products in 2026 and 2027?
A:Current capacity is sufficient for now, but Novanta is using the Novanta Growth System to increase capacity efficiently. Automation and additional capacity may be required as volumes grow beyond current levels.
Q:How does the semiconductor electronics market factor into the second half guidance?
A:Any risks associated with the semiconductor electronics market have been factored into the second half guidance. Novanta is shipping units into these applications in Q4, albeit at lower volumes than initially expected. The company remains well-positioned with sole-source designs and doubled content per unit, awaiting market recovery for higher volumes.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer or lacked clarity on the outlook for life sciences, stating it remains unclear. Additionally, while they discussed potential recovery of the $35 million held up due to China tariffs, they did not provide a definitive timeline or assurance of recovery.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI application
AI robotics
Advanced Surgery
Buckley
Corporate Participant
Kion acquisition
Leader IR
Research Division
advantage
application AI
application warehouse
capability warehouse
consumables
content
contract
development
digit Advanced
edge
investment
machine vision
opportunity
pace
playbook
player
portfolio
progress robotics
pump
sensing
software
subsystem
technology RFID
term market
throughput
tower
trade disruption
vision technology
warehouse robotics
NOVT Transcript
Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call and Q&A reveal a positive outlook for Novanta. Despite a slight decline in gross margin, strong growth is evident in multiple segments, such as Medical Solutions and Automation Enabling Technologies. The company's strategic initiatives, including regionalization and new product launches, are expected to drive future growth. The NVIDIA AI lab certification and strong bookings further bolster confidence. Although some uncertainties remain, particularly in cost management, the overall sentiment is optimistic, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call indicates positive growth in key segments like Medical Solutions and Automation, with strong bookings and a positive book-to-bill ratio. Despite a decline in operating cash flow, the company shows strong demand and momentum across segments, especially in robotics and automation. The Q&A session reveals strategic positioning in high-growth areas and effective capital deployment plans. The positive sentiment is bolstered by optimistic guidance and strong market demand, suggesting a likely positive stock price movement over the next two weeks.
Novanta Inc. (NOVT) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights strong new product revenue growth, improved customer bookings, and positive adjusted financial metrics despite temporary cash flow issues. The Q&A section reveals optimism about future growth in robotics and automation, with significant opportunities in the physical AI market. Margins are expected to improve with regional manufacturing strategies. While there are some concerns about specific segments, overall, the company's strategic initiatives and growth prospects suggest a positive stock price reaction.
Novanta Inc. (NOVT) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents a mixed picture. While there are positive aspects such as strong bookings growth, advanced surgery business growth, and promising new product launches, there are concerns with the decline in precision medicine sales and uncertain life sciences outlook. The Q&A reveals cautious guidance and unresolved tariff issues. The positive impact of the Kion acquisition and potential growth in warehouse robotics is offset by uncertainties in organic growth and market recovery, leading to a neutral stock price prediction.
NOVT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
